Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Small Cell Lung Carcinoma 14Triple Negative Breast Neoplasms 12Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 7Endometrial Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Esophageal Neoplasms 4NSCLC 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Squamous NSCLC 1Solid Tumor Cancer 1Solid Tumor 1Salivary Gland Malignant Neoplasms 1Respiratory Tract Neoplasms 1

Interventions

fluzoparib 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Platinum-sensitive Relapsed Ovarian Cancer × Carboplatin × Clear all
NCT06446206 2024-06-06

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

The First Hospital of Jilin University

Phase 2 Not yet recruiting
22 enrolled
Gynecologic

Platinum-sensitive Relapsed Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡